What newer iron formulations are available to raise ferritin levels in adults?

Newer Iron Formulations to Raise Ferritin Levels

The most effective newer iron formulations for raising ferritin levels are the high-dose intravenous preparations that allow total dose infusion (TDI) in 1-2 visits: ferric carboxymaltose, ferric derisomaltose (iron isomaltoside), ferumoxytol, and low molecular weight iron dextran, with newer oral options including ferric citrate, ferric maltol, and liposomal iron for patients who can tolerate oral therapy 1.

Intravenous Iron Formulations (Most Effective)

The newer IV iron preparations represent a significant advancement over older formulations like iron sucrose and ferric gluconate, which are limited to 200-250 mg per dose and require 4-7 visits for complete iron repletion 2.

High-Dose IV Iron Preparations

Ferric Carboxymaltose (Ferinject/Injectafer)

• Maximum single dose: 1000 mg (EMA) or 750 mg (FDA)
• Concentration: 50 mg/mL elemental iron
• Infusion time: 15 minutes for maximum dose
• Can achieve complete iron repletion in 1-2 visits 1
• Important caveat: Associated with hypophosphatemia in 50-74% of patients (the "6H syndrome": hyperphosphaturic hypophosphatemia triggered by high FGF23, causing hypovitaminosis D, hypocalcemia, secondary hyperparathyroidism, bone pain, osteomalacia, and fractures) 3

Ferric Derisomaltose/Iron Isomaltoside (Monofer/Monoferric)

• Maximum single dose: 20 mg/kg (EMA) or 1000 mg (FDA)
• Concentration: 100 mg/mL elemental iron (highest concentration available)
• Infusion time: >15 minutes for doses up to 1000 mg
• Allows complete iron repletion in a single visit 1
• Does not carry the same hypophosphatemia risk as ferric carboxymaltose 3

Ferumoxytol (Rienso/Feraheme)

• Maximum single dose: 510 mg
• Total dose: 1020 mg (given as two 510 mg doses)
• Concentration: 30 mg/mL elemental iron
• Infusion time: 15 minutes per dose
• Originally designed as MRI contrast agent 2
• Requires 2 visits for complete repletion

Low Molecular Weight Iron Dextran (Cosmofer/INFeD)

• Maximum single dose: 20 mg/kg (can exceed 1000 mg)
• Concentration: 50 mg/mL elemental iron
• Can be given as 1000 mg infusion in 1 hour 2
• Critical distinction: This is NOT the older high molecular weight iron dextran (Dexferrum, now off market) which had unacceptably high adverse event rates up to 28% 2
• Carries black box warning in US (but not Europe) despite lack of supporting evidence for current formulation 2
• Requires test dose or slow initiation per FDA label 2

Dialysate-Administered Iron (Newest Approach)

Ferric Pyrophosphate Citrate

• Recently FDA-approved at time of 2021 KDIGO conference 1
• Administered via dialysate in hemodialysis patients
• Delivers iron directly to circulating transferrin (bypasses reticuloendothelial macrophage uptake) 1
• Maintains hemoglobin without excessive iron store increases
• Reduces ESA and IV iron needs 1

Newer Oral Iron Formulations

While IV iron remains superior for efficacy, newer oral formulations offer advantages over traditional ferrous salts in terms of tolerability and absorption 1.

Ferric Citrate (Auryxia/Riona/Nephoxil)

• Dose: 210 mg elemental iron per tablet
• Dosing: 1 tablet 3 times daily with meals (non-dialysis CKD); 2 tablets 3 times daily (dialysis patients)
• Increases TSAT, ferritin, and hemoglobin 1
• Unique benefit: Also functions as phosphate binder, lowering serum phosphate and FGF23 levels 1
• Preliminary evidence suggests reduced hospitalization and mortality compared to usual care 1

Ferric Maltol (Feraccru/Accrufer)

• Dose: 30 mg elemental iron per capsule
• Dosing: 1 capsule twice daily 1
• Better tolerated than traditional ferrous salts
• Approved for IDA in adults with oral iron intolerance 1

Liposomal Iron (Ferrolip/SiderAL Forte)

• Dose: 30 mg elemental iron
• Dosing: 30 mg daily 1
• Avoids direct contact with intestinal mucosa
• Bypasses hepcidin-ferroportin block via uptake into intestinal M cells 1
• Small trial showed hemoglobin increase in non-dialysis CKD patients 1
• Limitation: Needs larger confirmatory trials

Sucrosomial Iron

• Recent research (2024) showed significantly higher improvement in hemoglobin (12.20 ± 0.1 g/dL) and ferritin levels compared to conventional oral iron salts 4
• Better safety and tolerability profile 4

Clinical Decision Algorithm

For IV Iron (Preferred for Rapid Ferritin Repletion):

1. Choose ferric derisomaltose or low molecular weight iron dextran if single-visit complete repletion is priority and you want to avoid hypophosphatemia risk
2. Choose ferric carboxymaltose if single-visit repletion is needed BUT monitor serum phosphate before repeated doses and in symptomatic patients 1
3. Choose ferumoxytol if 2-visit protocol is acceptable
4. Avoid iron sucrose and ferric gluconate for ambulatory patients—they require 4-7 visits and offer no safety or efficacy advantage over TDI formulations 2

For Oral Iron:

1. Start with ferric citrate if patient has CKD with hyperphosphatemia (dual benefit) 1
2. Use ferric maltol or liposomal iron if patient has failed traditional ferrous salts due to GI intolerance 1
3. Consider sucrosomial iron based on emerging evidence of superior efficacy 4
4. Dose once daily or every other day (not multiple times daily) since hepcidin remains elevated for 48 hours after iron intake, blocking further absorption 5

Important Safety Considerations

IV Iron Reactions:

• True anaphylaxis is extremely rare (<1:200,000) 6, 5
• Most reactions are complement activation-related pseudo-allergy (CARPA), not true allergy 5
• Moderate to severe reactions affect <1% of patients across all modern preparations 3
• Management: Stop infusion for mild reactions, restart 15 minutes later at slower rate; avoid diphenhydramine as side effects mimic worsening reaction 5

Hypophosphatemia Risk:

• Specific to ferric carboxymaltose (50-74% incidence) 3
• Can cause severe, potentially irreversible complications: bone pain, osteomalacia, fractures 3
• Monitor phosphate levels before repeated doses 1

Infection Risk:

• Withhold IV iron during active infections (these patients excluded from RCTs) 1
• High-dose strategies up to PIVOTAL trial levels appear safe 1

Common Pitfall: Using iron sucrose or ferric gluconate in ambulatory settings when TDI formulations would accomplish the same goal in 1-2 visits instead of 4-7, reducing cost, inconvenience, and extravasation risk 2.